Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.98 Analyst target: $7.87 Upside: 703.06%
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.